Targeting miRNA-mediated immune activation in humanized mice

This abstract has open access
Abstract Summary

Islet autoimmunity, the presymptomatic phase of type 1 diabetes (T1D), is characterized by aberrations in immune activation versus T-cell tolerance. However, the molecular underpinnings remain poorly understood. MiRNAs regulate multiple targets and thereby can alter complex cellular states. During recent onset of islet autoimmunity, increased miRNA92a and miRNA181a expression in CD4+T cells contribute to aberrant immune activation and impaired regulatory T cell (Treg) induction. Mechanistically, we showed that miRNA92a increases T follicular helper (TFH) cell differentiation, while miRNA181a enhances the sensitivity of CD4+T cells to antigenic stimulation involving increased NFAT5 signaling. Both miRNAs inhibit negative regulators of T cell activation and impair Treg induction in vitro. Blocking these miRNAs or NFAT5 in NOD mice reduces immune activation paralleled by local increases in Treg frequencies. Here, using humanized mice (murine MHC-deficient, HLA-DQ8-transgenic, NOD-Scid-IL2Rg-KO) reconstituted with human hematopoietic cells, we investigated the role of these miRNAs and downstream signaling pathways in immune activation vs. Treg induction. Inhibiting miRNA92a reduced immune activation as highlighted by significantly decreased pancreas-infiltrating insulin-specific CD4+T cells accompanied by decreased insulin-specific TFH precursors (insulin-specific CD4+CXCR5+PD1highT cells [% of insulin-specific CD4+]: control antagomir: 18.8±5.3% vs. miRNA92a antagomir: 3.6±3.6%; p<0.05). Moreover, NFAT5 blockade significantly increased Treg frequencies in the peripheral blood (CD25highFxop3highTregs: vehicle: 9.9±1.2% vs. NFAT5 inhibitor: 14.8±1.0%; p<0.05), as well as in the spleen of humanized mice. These initial findings highlight positive effects of miRNA92a or NFAT5 inhibition on reducing immune activation in the setting of a human immune system in vivo. Further studies will test the implication of these molecules as targetable signaling intermediates to interfere with aberrant immune activation during ongoing islet autoimmunity

Submission ID :
IDS82110
Submission Type
Abstract Topics
Helmholtz Zentrum München
Helmholtz Zentrum München
Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany
Helmholtz Zentrum München

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
2 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org